Close Menu

NEW YORK(GenomeWeb) – HealthTell said today that it has received a $225,000 SBIR grant from the National Institutes of Health.

The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer, and glioblastoma multiforme, specifically.

According to HealthTell, the company aims through the project to demonstrate its platform's ability to distinguish primary brain cancers from brain cancers arising as metastases from other sites; and to differentiate brain cancer subtypes and grades of malignant gliomas.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.

Aug
22
Sponsored by
BC Platforms

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.